Loading...
Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK.
Loncaster, Juliette A Armstrong, Anne C Howell, Sacha J Wilson, Gregory Welch, Richard Chittalia, Abbas Valentine, W Bundred, N
Loncaster, Juliette A
Armstrong, Anne C
Howell, Sacha J
Wilson, Gregory
Welch, Richard
Chittalia, Abbas
Valentine, W
Bundred, N
Citations
Altmetric:
Abstract
The National Institute for Health and Clinical Excellence (NICE) recommended the Oncotype DX(®) Breast Recurrence Score(®) (RS) assay as an option for informing adjuvant chemotherapy decisions in node-negative, oestrogen receptor (ER)+, human epidermal growth factor receptor 2 (HER2)-negative early breast cancer assessed to be at intermediate risk of recurrence based on clinicopathological factors. We evaluated the impact of RS testing on adjuvant chemotherapy decision-making in routine clinical practice in a UK Cancer Network.
Description
Date
2017-01-09
Publisher
Collections
Files
Keywords
Type
Article
Citation
Impact of Oncotype DX Breast Recurrence Score testing on adjuvant chemotherapy use in early breast cancer: real world experience in Greater Manchester, UK. 2017, Eur J Surg Oncol